{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:37:26Z","timestamp":1773772646503,"version":"3.50.1"},"reference-count":33,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1134\/s1607672924700844","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T05:03:28Z","timestamp":1718082208000},"page":"140-147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Use of \u201cAcellbia\u201d\u2014A Biosimilar of Rituximab in Systemic Sclerosis"],"prefix":"10.1134","volume":"517","author":[{"given":"L. P.","family":"Ananyeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Garzanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. V.","family":"Desinova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. U.","family":"Shayakhmetova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. N.","family":"Starovoitova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. A.","family":"Koneva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. B.","family":"Ovsyannikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. I.","family":"Glukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. L.","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"7532_CR1","first-page":"201","volume":"55","author":"E.V. Nasonov","year":"2017","unstructured":"Nasonov, E.V., Mazurov, V.I., Usacheva, Y.V., Chernyaeva, E.V., Ustyugov, Y.Y., et al., Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases, Nauchno-Prakt. \n               Revmatol., 2017, vol. 55, no. 2, pp. 201\u2013210.","journal-title":"Revmatol."},{"key":"7532_CR2","first-page":"1","volume":"57","author":"E.L. Nasonov","year":"2019","unstructured":"Nasonov, E.L., Beketova, T.V., Ananyeva, L.P., Vasilyev, V.I., Solovyev, S.K., and Avdeeva, A.S., Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases, Nauchno-Prakt. \n               Revmatol., 2019, vol.\u00a057, pp. 1\u201340.","journal-title":"Revmatol."},{"key":"7532_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","volume":"61","author":"J. Barnas","year":"2019","unstructured":"Barnas, J., Looney, R., and Anolik, J., B cell targeted therapies in autoimmune disease, Curr. Opin. Immunol., 2019, vol. 61, pp. 92\u201399.","journal-title":"Curr. Opin. Immunol."},{"key":"7532_CR4","volume-title":"Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab (Anti-B-Cell Therapy in Rheumatology: Focus on Rituximab)","year":"2012","unstructured":"Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab (Anti-B-Cell Therapy in Rheumatology: Focus on Rituximab), Nasonov, E.L., Ed., Moscow: IMA-PRESS, 2012."},{"key":"7532_CR5","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"C.P. Denton","year":"2017","unstructured":"Denton, C.P. and Khanna, D., Systemic sclerosis, Lancet, 2017, vol. 390, no. 10103, pp. 1685\u20131699.","journal-title":"Lancet"},{"key":"7532_CR6","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s10067-021-05665-z","volume":"40","author":"K. Melissaropoulos","year":"2021","unstructured":"Melissaropoulos, K. and Daoussis, D., B cells in systemic sclerosis: from pathophysiology to treatment, Clin. Rheumatol., 2021, vol. 40, no. 7, pp. 2621\u20132631.","journal-title":"Clin. Rheumatol"},{"key":"7532_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D. Daoussis","year":"2017","unstructured":"Daoussis, D., Melissaropoulos, K., Sakellaropoulos, G., Antonopoulos, I., Markatseli, T.E., et al., A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease, Semin. Arthritis Rheum., 2017, vol. 46, no. 5, pp. 625\u2013631.","journal-title":"Semin. Arthritis Rheum."},{"key":"7532_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","volume":"44","author":"S.L. Bosello","year":"2015","unstructured":"Bosello, S.L., De Luca, G., Rucco, M., Berardi, G., Falcione, M., et al., Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis, Semin. Arthritis Rheum., 2015, vol.\u00a044, no. 4, pp. 428\u2013436.","journal-title":"Semin. Arthritis Rheum."},{"key":"7532_CR9","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M. Elhai","year":"2019","unstructured":"Elhai, M., Boubaya, M., Distler, O., Smith, V., Matucci-Cerinic, M., et al., Outcomes of patients with systemic sclerosis treated with Rituximab in contemporary practice: a prospective cohort study, Ann. Rheum. Dis., 2019, vol. 78, no. 7, pp. 979\u2013987.","journal-title":"Ann. Rheum. Dis"},{"key":"7532_CR10","first-page":"628","volume":"54","author":"E.L. Nasonov","year":"2017","unstructured":"Nasonov, E.L., Biosimilars in rheumatology, Nauchno-Prakt. \n               Revmatol., 2017, vol. 54, no. 6, pp. 628\u2013640.","journal-title":"Revmatol."},{"key":"7532_CR11","first-page":"510","volume":"54","author":"E.L. Nasonov","year":"2016","unstructured":"Nasonov, E.L., Zonova, E.V., Ivanova, O.N., Knyazeva, L.A., Mazurov, V.I., et al., The results of a phase III comparative clinical trial of rituximab (Acellbia\u00ae and Mabthera\u00ae) in rheumatoid arthritis (The BIORA study). Nauchno-Prakt. \n               Revmatol., 2016, vol. 54, no. 5, pp. 510\u2013519.","journal-title":"Revmatol."},{"key":"7532_CR12","first-page":"351","volume":"55","author":"E.L. Nasonov","year":"2017","unstructured":"Nasonov, E.L., Mazurov, V.I., Zonova, E.V., Knyazeva, L.A., Marusenko, I.M., et al., The efficacy and safety of Rituximab Biosimilar (ACELLBIA\u00ae) in rheumatoid arthritis as the first biological agent: results of phase III (alterra) clinical trial, Nauchno-Prakt. \n               Revmatol., 2017, vol. 55, no. 4, pp. 351\u2013359.","journal-title":"Revmatol"},{"key":"7532_CR13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F. van den Hoogen","year":"2013","unstructured":"van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S., Baron, M., et al., 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative, Arthritis Rheum., 2013, vol. 65, no. 11, pp.\u00a02737\u20132747.","journal-title":"Arthritis Rheum."},{"key":"7532_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/ard.60.6.592","volume":"60","author":"G. Valentini","year":"2001","unstructured":"Valentini, G., European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes, Ann. Rheum. Dis., 2001, vol. 60, no. 6, pp. 592\u2013598.","journal-title":"Ann. Rheum. Dis"},{"key":"7532_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D. Khanna","year":"2017","unstructured":"Khanna, D., Furst, D.E., Clements, P.J., Allanore, Y., Baron, M., et al., Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis, J. Scleroderma Relat. Disord., 2017, vol. 2, no.\u00a01, pp. 11\u201318.","journal-title":"J. Scleroderma Relat. Disord."},{"key":"7532_CR16","doi-asserted-by":"crossref","unstructured":"Pope, J., Measures of systemic sclerosis (scleroderma): Health assessment questionnaire (HAQ) and Scleroderma Haq (Shaq), physician- and patient-rated Global Assessments, symptom burden index (SBI), University of California, Los Angeles, scleroderma clinical trials, Arthritis Care Res., 2011, vol. 63, no. S11.","DOI":"10.1002\/acr.20598"},{"key":"7532_CR17","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s10067-021-05698-4","volume":"40","author":"M. Moradzadeh","year":"2021","unstructured":"Moradzadeh, M., Aghaei, M., Mehrbakhsh, Z., Arab-Bafrani, Z., and Abdollahi, N., Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSC): systematic review and meta-analysis, Clin. Rheumatol., 2021, vol. 40, no. 10, pp. 3897\u20133918.","journal-title":"Clin. Rheumatol"},{"key":"7532_CR18","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R. Tang","year":"2020","unstructured":"Tang, R., Yu, J., Shi, Y., Zou, P., Zeng, Z., et al., Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis, Int. Immunopharmacol., 2020, vol. 83, p. 106389.","journal-title":"Int. Immunopharmacol"},{"key":"7532_CR19","doi-asserted-by":"crossref","unstructured":"de Figueiredo Caldas, M.M., de Azevedo, K.P., de\u00a0Fran\u00e7a Nunes, A.C., de Oliveira, V.H., Pimenta,\u00a0I.D.S.F., et al., Is Rituximab effective for systemic sclerosis? A systematic review and meta-analysis, Adv. Rheumatol., 2021, vol. 61, no. 1.","DOI":"10.1186\/s42358-021-00170-y"},{"key":"7532_CR20","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.3390\/jcm11154631","volume":"11","author":"S. Ebata","year":"2022","unstructured":"Ebata, S., Yoshizaki-Ogawa, A., Sato, S., and Yoshizaki, A., New era in systemic sclerosis treatment: recently approved therapeutics, J. Clin. Med., 2022, vol. 11, no.\u00a015, pp. 4631.","journal-title":"J. Clin. Med"},{"key":"7532_CR21","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S. Jordan","year":"2014","unstructured":"Jordan, S., Distler, J.H., Maurer, B., Huscher, D., van Laar, J.M., et al., Effects and safety of Rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group, Ann. Rheum. Dis., 2014, vol. 74, no. 6, pp. 1188\u20131194.","journal-title":"Ann. Rheum. Dis"},{"key":"7532_CR22","doi-asserted-by":"crossref","unstructured":"Garzanova, L., Ananyeva, L.P., Koneva, O., Desinova, O., Ovsyannikova, O., et al., Changes of lung function and skin fibrosis in patients with interstitial lung disease associated with systemic sclerosis on Rituximab therapy\u2014comparison of the efficacy of biosimilar Acellbia and Mabthera, Ann. Rheum. Dis., 2022, vol. 81, suppl. 1.","DOI":"10.1136\/annrheumdis-2022-eular.3640"},{"key":"7532_CR23","first-page":"38","volume":"27","author":"P.I. Novikov","year":"2018","unstructured":"Novikov, P.I., Zykova, A.S., Shchegoleva, E.M., Bulanov, N.M., Smitienko, I.O., and Moiseev, S.V., Short-term efficacy and safety of biosimilar rituximab in patients with ANCA-associated vasculitis, Klin. Farmakol. Ter., 2018, vol. 27, no. 2, pp. 38\u201342.","journal-title":"Klin. Farmakol. Ter"},{"key":"7532_CR24","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1093\/rheumatology\/keaa136","volume":"59","author":"C. Campochiaro","year":"2020","unstructured":"Campochiaro, C., De Luca, G., Lazzaroni, M.G., Zanatta, E., Bosello, S.L., et al., Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study, Rheumatology, 2020, vol. 59, no. 12, pp. 3731\u20133736.","journal-title":"Rheumatology"},{"key":"7532_CR25","doi-asserted-by":"publisher","first-page":"107524","DOI":"10.1016\/j.intimp.2021.107524","volume":"95","author":"N.S. Xing","year":"2021","unstructured":"Xing, N.S., Fan, G.Z., Yan, F., Liu, Y.P., and Zhang, R., Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis, Int. Immunopharmacol., 2021, vol. 95, p. 107524.","journal-title":"Int. Immunopharmacol"},{"key":"7532_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","volume":"60","author":"R.P. Goswami","year":"2020","unstructured":"Goswami, R.P., Ray, A., Chatterjee, M., Mukherjee, A., Sircar, G., and Ghosh, P., Rituximab in the treatment of systemic sclerosis\u2013related interstitial lung disease: a systematic review and meta-analysis, Rheumatology, 2020, vol. 60, no. 2, pp. 557\u2013567.","journal-title":"Rheumatology"},{"key":"7532_CR27","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A. Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina, A., Walker, K.M., and Pope, J.E., Treatment algorithms for systemic sclerosis according to experts, Arthritis Rheumatol., 2018, vol. 70, no. 11, pp. 1820\u20131828.","journal-title":"Arthritis Rheumatol"},{"key":"7532_CR28","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/1346-8138.15079","volume":"46","author":"S. Ebata","year":"2019","unstructured":"Ebata, S., Yoshizaki, A., Fukasawa, T., Miura, S., Takahashi, T., et al., Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease, J. Dermatol., 2019, vol. 46, no. 11, pp. 1006\u20131013.","journal-title":"J. Dermatol"},{"key":"7532_CR29","first-page":"57","volume":"60","author":"L.P. Ananyeva","year":"2022","unstructured":"Ananyeva, L.P., Garzanova, L.A., Koneva, O.A., Starovoytova, M.N., Desinova, O.V., et al., Anti-topoisomerase 1 antibody level changes after B cell depletion therapy in systemic sclerosis, Nauchno-Prakt. \n               Revmatol., 2022, vol. 60, no. 1, pp. 57\u201363.","journal-title":"Revmatol"},{"key":"7532_CR30","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","volume":"107","author":"M. Makatsori","year":"2014","unstructured":"Makatsori, M., Kiani-Alikhan, S., Manson, A.L., Verma, N., Leandro, M., et al., Hypogammaglobulinaemia after rituximab treatment\u2013incidence and outcomes, QJM, 2014, vol. 107, no. 10, pp. 821\u2013828.","journal-title":"QJM"},{"key":"7532_CR31","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M. Thiebaut","year":"2018","unstructured":"Thiebaut, M., Launay, D., Rivi\u00e8re, S., Mah\u00e9vas, T., Bellakhal, S., et al., Efficacy and safety of Rituximab in systemic sclerosis: French retrospective study and literature review, Autoimmun. Rev., 2018, vol. 17, no. 6, pp.\u00a0582\u2013587.","journal-title":"Autoimmun. Rev"},{"key":"7532_CR32","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"D.M. Roberts","year":"2015","unstructured":"Roberts, D.M., Jones, R.B., Smith, R.M., Alberici, F., Kumaratne, D.S., et al., Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease, J. Autoimmun., 2015, vol. 57, pp. 60\u201365.","journal-title":"J. Autoimmun"},{"key":"7532_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.14412\/1996-7012-2018-2-58-63","volume":"12","author":"R.O. Dreval","year":"2018","unstructured":"Dreval, R.O. Evaluating the effect of a Russian rituximab biosimilar used to treat patients with rheumatoid arthritis on healthcare budgets, Mod. Rheumatol. J., 2018, vol. 12, no. 2, pp. 58\u201363.","journal-title":"Mod. Rheumatol. J."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924700844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672924700844","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924700844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:20:41Z","timestamp":1773760841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672924700844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["7532"],"URL":"https:\/\/doi.org\/10.1134\/s1607672924700844","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors of this work declare that they have no conflicts of interest. The authors are solely responsible for providing the final version of the manuscript. All authors took part in developing the concept of the article and writing the manuscript. The final version of the manuscript was approved by all authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}},{"value":"The study was approved by the local ethics committee of the Nasonova Research Institute of Rheumatology (protocol no. 10 dated June 3, 2021). All study participants signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}]}}